Readystate Asset Management’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34M Buy
1,605,820
+303,958
+23% +$6.5M 1.16% 14
2026
Q1
$28.5M Sell
1,301,862
-541,348
-29% -$12M 1.28% 15
2025
Q4
$39.6M Buy
1,843,210
+524,920
+40% +$9.21M 1.61% 11
2025
Q3
$15.4M Sell
1,318,290
-35,296
-3% -$351K 0.66% 43
2025
Q2
$12.6M Buy
1,353,586
+1,129,346
+504% +$9.26M 0.39% 60
2025
Q1
$1.51M Buy
+224,240
New +$2.15M 0.05% 342

Other funds holding IMNM

Readystate Asset Management's IMNM Position: Q2 2026 in Review

Readystate Asset Management increased its Immunome (IMNM) stake by 23% in Q2 2026, buying an estimated $6.5M and bringing the position to 1,605,820 shares worth $34M. The position accounts for 1.16% of the portfolio, ranked #14.

Readystate Asset Management first reported a position in IMNM in Q1 2025 and has held it in 6 quarters since. The position peaked at $39.6M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Readystate Asset Management held 1,605,820 shares of Immunome worth $34M as of Q2 2026.
  • Readystate Asset Management bought 303,958 Immunome shares in Q2 2026, an estimated $6.5M.
  • Immunome made up 1.16% of Readystate Asset Management's portfolio in Q2 2026, its #14 holding.
  • Readystate Asset Management first reported a position in Immunome in Q1 2025 and has held it in 6 quarters since.
  • Readystate Asset Management's Immunome position peaked at $39.6M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.